ENTITY
Eisai Co Ltd

Eisai Co Ltd (4523 JP)

94
Analysis
Health CareJapan
Eisai Co., Ltd. produces prescription drugs and medical equipment and sells mainly to sales agents and subsidiaries. Through its subsidiary, Sanko Junyaku, the Company produces and sells diagnostic drugs. Eisai also markets its products through related companies in the US, Europe, and Asia. The Company also manufactures and sells foods, livestock feeds, chemical, and agrochemicals.
more
Refresh
bearishEisai Co Ltd
09 Mar 2024 09:30

Eisai Co Ltd (4523 JP): Despite Sluggish Launch, Ambitious Long-Term Target Set for Leqembi

Eisai projects Leqembi revenue to reach ¥1.6T by FY33 with early and pre-clinical AD indications. As of January, Leqembi reached just 2K patients...

Logo
372 Views
Share
bearishEisai Co Ltd
03 Jan 2024 09:30

Eisai Co Ltd (4523 JP): Why Performance Reversal Is Not Expected in Near-Term

​Eisai shares are on downtrend due to disappointment with Alzheimer's drug. Top-selling drug Lenvima faces patent expiration in 2025. Eisai seeks...

Logo
629 Views
Share
bullishEisai Co Ltd
05 Aug 2023 17:52

Eisai Co (4523 JP): Better-Than-Expected Q1FY24 Result; Reaffirmed FY24 Guidance

Eisai reported 7%  revenue growth in Q1, due to the growth of Lenvima mainly in the U.S. and Dayvigo in Japan. The company expects a big jump in...

Logo
368 Views
Share
bullishEisai Co Ltd
07 Jul 2023 18:12

Eisai Co Ltd (4523 JP): Becomes the Best Alzheimer’s Disease Play After Full FDA Nod

Eisai has received FDA traditional approval for Leqembi injection for the treatment of Alzheimer’s Disease. Following the approval, CMS confirmed...

Logo
473 Views
Share
bullishEisai Co Ltd
25 Jun 2023 17:39

Eisai Co (4523 JP): Alzheimer’s Drug Approaching Full FDA Approval; Other Countries to Follow Soon

The PDUFA action date for traditional approval of Leqembi for the treatment of Alzheimer’s disease has been set for July 6. Leqembi is expected to...

Logo
349 Views
Share
x